De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Short-Bowel Syndrome: A Case Report

• Published in: JPEN. Journal of parenteral and enteral nutrition Vol. 45; no. 3; p. 652
• Main Authors: Pevny, Sophie, Pape, Ulrich-Frank, Elezkurtaj, Sefer, Rieger, Anja, Jürgensen, Christian, Blüthner, Elisabeth, Jochum, Christoph, Tacke, Frank, Maasberg, Sebastian
• Format: Journal Article
• Language: English
• Published: United States 01.03.2021
• Subjects: Adenoma - complications; Adenoma - drug therapy; Gastrointestinal Agents - therapeutic use; Humans; Jejunum; Peptides; Short Bowel Syndrome - complications; Short Bowel Syndrome - drug therapy; intestinal failure; duodenal adenoma; parenteral nutrition; jejunal adenoma; teduglutide; endoscopy; glucagon-like peptide 2; short bowel syndrome
• ISSN: 1941-2444
• DOI: 10.1002/jpen.1982

The glucagon-like peptide-2 (GLP-2) analogue teduglutide is a medical treatment option for patients with short-bowel syndrome-associated chronic intestinal failure. Because studies in mice have shown that GLP-2 analogues may promote the growth of colonic neoplasms, surveillance colonoscopies before and during teduglutide therapy were recommended. The occurrence of small-intestinal neoplasms has not been reported so far, except for a recent report about de novo development of hamartomatous duodenal polyps. We report a case of de novo development of small-intestinal premalignant adenomatous polyps in both bulbar duodenum and distal jejunum in a patient treated with teduglutide for 41 months. Therefore, additional endoscopic surveillance of the upper gastrointestinal tract may be advised during teduglutide therapy for early detection and removal of potential small-bowel adenomas.